Vietnam Diabetes Care Drugs Market Outlook to 2028

Vietnam Diabetes Care Drugs Market Overview

The Vietnam Diabetes Care Drugs Market is valued at USD 200 million, based on a five-year historical analysis. This market is primarily driven by the rising prevalence of diabetes in both urban and rural populations, increased healthcare expenditure, and the governments efforts to enhance diabetes care. The country has seen a surge in demand for both insulin and oral anti-diabetic drugs, particularly with the growing availability of biosimilar drugs that help meet the demand in low-income groups.

In terms of geographic dominance, major cities like Ho Chi Minh City and Hanoi lead the market due to their well-established healthcare infrastructure, higher urbanization rates, and better access to modern healthcare services. Additionally, these cities have a higher concentration of diabetes centers and healthcare professionals, allowing for better diagnosis and treatment of diabetes compared to rural areas.

The Vietnamese government has implemented the National Diabetes Program, which, by 2024, has screened over 10 million individuals for diabetes and pre-diabetes. This initiative has led to earlier diagnosis and a higher number of patients receiving timely medication, thus driving demand for diabetes care drugs. The program also includes public health campaigns aimed at increasing awareness of diabetes management, further boosting market growth.

Vietnam Diabetes Care Drugs Market Segmentation

By Drug Type: The market is segmented by drug type into insulin, oral anti-diabetic drugs, GLP-1 receptor agonists, SGLT-2 inhibitors, and others (including alpha-glucosidase inhibitors and amylinomimetics). Insulin currently holds the dominant market share due to its widespread necessity for type 1 diabetic patients and its increasing use in type 2 diabetes patients who fail to control blood sugar with oral medications alone. Furthermore, advancements in insulin delivery methods, such as prefilled insulin pens and insulin pumps, have made it easier for patients to administer their doses, contributing to the dominance of this sub-segment.

By Patient Type: The market is also segmented by patient type, which includes Type 1 diabetes, Type 2 diabetes, gestational diabetes, and pre-diabetes. Type 2 diabetes represents the largest share of the market due to the growing aging population, unhealthy dietary patterns, and a rise in sedentary lifestyles in urban areas. Moreover, government campaigns aimed at diabetes awareness and early diagnosis have further elevated the number of diagnosed Type 2 diabetic patients, boosting the demand for anti-diabetic drugs in this sub-segment.

Vietnam Diabetes Care Drugs Market Competitive Landscape

The market is dominated by key global and local players who have a influence on market dynamics. The market sees a high level of consolidation, with several major companies like Sanofi, Novo Nordisk, and Eli Lilly having a large presence in insulin and other diabetes care drugs. Additionally, local manufacturers like Vinphaco are also playing a pivotal role in catering to domestic demand, especially in rural areas where affordability is a concern.

Company

Establishment Year

Headquarters

Revenue

No. of Products

R&D Investment

Market Penetration

Distribution Network

Strategic Partnerships

Key Therapeutic Areas

Sanofi

1973

Paris, France

Novo Nordisk

1923

Bagsvrd, Denmark

Eli Lilly

1876

Indianapolis, USA

Merck & Co.

1891

Kenilworth, USA

Vinphaco

1958

Phu Tho, Vietnam

Vietnam Diabetes Care Drugs Market Analysis

Market Growth Drivers

Rising Prevalence of Diabetes in Vietnam: Vietnam has been witnessing an alarming rise in the number of diabetes cases, with over 5.4 million individuals diagnosed in 2024. This has led to an increasing demand for diabetes care drugs in the country. According to government health records, the diabetic population in Vietnam has been growing steadily, driven by changing lifestyles and dietary habits, particularly in urban areas. These factors are directly contributing to higher drug consumption for diabetes management.

Government Policies Supporting Diabetes Treatment: The Vietnamese government, through the Ministry of Health, has introduced various diabetes management programs aimed at improving the accessibility and affordability of diabetes care drugs. By 2024, over 800,000 individuals are benefiting from government-funded initiatives that subsidize insulin and other diabetes-related medications. These initiatives focus on both prevention and treatment, contributing to market growth by making essential drugs more affordable and widely available.

Growing Demand for Advanced Treatment Options: The demand for newer, more advanced diabetes medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, has been rising. In 2024, an estimated 1.2 million Vietnamese patients have shifted to advanced treatment options, seeking better glycemic control and fewer side effects. This growing preference for innovative drugs has resulted in increased sales of branded diabetes medications in Vietnam.

Market Challenges

Limited Access to Healthcare in Rural Areas: Vietnam's rural population, which accounts for approximately 60 million people in 2024, continues to face limited access to healthcare facilities and diabetes medications. Many rural areas lack sufficient healthcare infrastructure, resulting in delayed diagnosis and inadequate treatment of diabetes. This urban-rural healthcare gap hinders the market growth for diabetes care drugs, as a large portion of the population remains underserved.

Low Awareness of Diabetes Management: Despite the increasing prevalence of diabetes, awareness of proper diabetes management remains low in Vietnam. Surveys conducted in 2024 indicate that nearly 35% of diabetic patients in rural areas are unaware of proper treatment protocols, leading to underutilization of prescribed drugs. This lack of awareness limits the demand for diabetes care drugs, as many patients remain untreated or are not compliant with their medication regimens.

Vietnam Diabetes Care Drugs Market Future Outlook

The Vietnam Diabetes Care Drugs industry is expected to experience substantial growth over the next five years, driven by the continuous rise in diabetes prevalence, technological advancements in drug delivery methods, and expanding government programs aimed at improving public health.

Future Market Opportunities

Increased Adoption of Personalized Diabetes Care: Over the next five years, Vietnam is expected to see a shift toward personalized diabetes care, with more than 2 million patients projected to adopt tailored treatment plans by 2029. This trend will drive the demand for advanced diabetes medications, as patients seek more individualized solutions to manage their condition effectively.

Expansion of Biosimilar Insulin Availability: Biosimilar insulin products are expected to gain widespread acceptance in Vietnam by 2029, with the number of patients using biosimilar insulins projected to surpass 800,000. These more affordable alternatives will reduce the cost burden on patients and the healthcare system, driving growth in the diabetes care drugs market.
Please Note: It will take 5-7 business days to complete the report upon order confirmation